Ventilator-Associated Pneumonia Market Demand, Growth, Application and Forecast to 2027

[Priya Raut]

Market Synopsis:

Ventilator-associated pneumonia is a respiratory disease caused to patients on ventilators. Increasing cases of respiratory diseases are expected to have a positive influence on the growth pattern of the market. According to Market Research Future (MRFR)’s study, the global ventilator-associated pneumonia market is projected to expand at a steady pace over the assessment period 2018 to 2023.

The increasing cases of brain injuries owing to accidents and other hazards are also poised to favor the proliferation of the ventilator-associated pneumonia market over the next couple of years. However, factors such as high ventilator charges, expensive diagnostic tests, risks associated with ventilators, etc. are prognosticated to undermine pace of market growth in the years to come.

Competitive Dashboard:

The noted players of the global ventilator-associated pneumonia market studied in this MRFR report are Adenium Biotech ApS (Denmark), Merck & Co., Inc. (U.S.), AstraZeneca (UK), Nabriva Therapeutics AG (Austria), and MedImmune (US).

Market Segmentation:

By diagnosis, the global ventilator-associated pneumonia market has been segmented into radiological examination, clinical examination, microbiological analysis, and others. The microbiological analysis segment has been further sub-segmented into nonquantitative or semi-quantitative airway sampling, quantitative cultures of airway specimens, and blood and pleural fluid cultures.

On the basis of mode of treatment, the ventilator-associated pneumonia market has been segmented into hospital care, homecare, and others.

Regional Analysis:

The global ventilator-associated pneumonia market, on the basis of region, has been segmented into four key regions, namely Americas, Europe, Asia Pacific, and the Middle East and Africa (MEA). The growth trajectory of the market is expected to be dictated by Americas owing to the presence of a developed healthcare infrastructure coupled with rising healthcare expenditure in North America. The region is also burdened with a huge patient population which is prognosticated to drive the expansion of the ventilator-associated pneumonia market in the region over the next couple of years. Exponential growth in the population of older adults is observed in the recent years. According to the estimations published by the U.S. Census Bureau, Americas will have 19.7 million senior citizens by 2060. This, in turn, is projected to boost the revenue creation of the regional market in the years to come.

Europe is anticipated to stand firm at the second spot in the global market place over the next few years. It has been published by the European respiratory society, that 50% of deaths caused in the region is due to respiratory diseases. Rising cases of respiratory disorders are likely to have a positive influence on the expansion of the ventilator-associated pneumonia market in the forthcoming years. Thus, the regional market’s future trajectory is likely to remain highly lucrative over the next few years.